New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:25 EDTBA, BA, LLY, LLYSenate Judiciary Committee to hold a hearing
The Subcommittee on Crime and Terrorism holds a hearing entitled, "Economic Espionage and Trade Secret Theft: Are Our Laws Adequate for Today’s Threats? with Vice President Paul Hoffman of The Boeing Company and Vice President Doug Norman of Eli Lilly & Company on May 13 at 2:30 pm. Webcast Link
News For BA;LLY From The Last 14 Days
Check below for free stories on BA;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 16, 2014
06:27 EDTLLYAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
September 15, 2014
17:40 EDTBABoeing awarded $130M government contract modification
Boeing Company, Mesa, Arizona, was awarded a $130M modification to fixed-price incentive, full rate production contract W58RGZ-12-C-0055; the cumulative total of the contract, before this modification, was $1.16B. This is an undefinitized contract action to build seven new Apache AH-64E helicopters. FY13 and FY14 other funds in the amount of $19.2M were obligated at the time of the award. Work will be performed in Mesa, Arizona, with an estimated completion date of March 31, 2017.
17:28 EDTBABoeing awarded $293.2M government contract modification
Subscribe for More Information
07:42 EDTBAMorgan Stanley to hold a conference
Subscribe for More Information
07:26 EDTLLYPiper Jaffray to hold a conference
Subscribe for More Information
07:22 EDTBAAir Force Association to hold a conference
Subscribe for More Information
September 12, 2014
08:02 EDTLLYEli Lilly announces Cyramza Phase III cancer trial meets primary endpoint
Subscribe for More Information
08:01 EDTLLYEli Lilly announces Cyramza Phase III cancer trial meets primary endpoint
Eli Lilly announced that the RAISE trial, a Phase III study of ramucirumab in combination with chemotherapy in patients with metastatic colorectal cancer, met its primary endpoint of overall survival. The global, randomized, double-blind study compared ramucirumab plus FOLFIRI to placebo plus FOLFIRI as a second-line treatment in patients with mCRC after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine in the first-line setting. RAISE showed a statistically significant improvement in overall survival in patients treated with ramucirumab plus FOLFIRI compared to placebo plus FOLFIRI. The study also showed a statistically significant improvement in progression-free survival in the ramucirumab-plus-FOLFIRI arm compared to the placebo-plus-FOLFIRI arm.
September 11, 2014
09:01 EDTBAAlcoa signs multiyear supply contract with Boeing valued at over $1B
Alcoa (AA) has signed a long-term contract to supply aluminum sheet and plate products to Boeing (BA). The multiyear contract, valued at more than $1B, is the largest ever between the two companies. Notably, the agreement makes Alcoa sole supplier to Boeing for wing skins on all of its metallic structure airplanes. Alcoa plate products, used in applications such as wing ribs, wing skins or other structural parts of the aircraft, will also be on every Boeing platform, including the 787 Dreamliner. Finally, the agreement establishes a foundation for continued collaboration on new, high-strength and corrosion-resistant alloys, including aluminum-lithium that could be used for complex structural applications.
September 10, 2014
09:14 EDTBABoeing receives first order for 502 Phoenix small satellite
Boeing received its first commercial order for the 502 Phoenix small satellite from HySpecIQ of Washington, D.C. The satellites will carry the commercial remote sensing industry’s first hyperspectral payload, capable of providing spectral imaging fidelity. Boeing will deliver a complete satellite system initially consisting of two satellites, available for launch in 2018, command and control operations, image processing, and data storage of collected imagery. The contract includes options for long-term operations and maintenance.
07:04 EDTLLYEU grants marketing authorization for Eli Lilly's insulin glargine product
The European Commission granted marketing authorization for Eli Lilly and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim alliance. It received a positive recommendation from the Committee for Medicinal Products for Human Use on June 26. The marketing authorisation for the alliance's insulin glargine product is based upon a comprehensive clinical data program. The application included results from pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in patients with type 1 and type 2 diabetes.
September 9, 2014
09:37 EDTBABoeing announces agreement with GA Telesis
Subscribe for More Information
06:17 EDTBABoeing up against pressure to boost 737 production rate, Reuters says
Subscribe for More Information
September 8, 2014
16:18 EDTBAOn The Fly: Closing Wrap
Subscribe for More Information
12:18 EDTBAOn The Fly: Midday Wrap
Subscribe for More Information
09:35 EDTBARyanair places order for up to 200 Boeing 737 MAX
Ryanair (RYAAY) confirmed an agreement with Boeing (BA) to purchase up to 200 new Boeing 737 MAX 200 aircraft, including 100 firm orders and 100 options. When finalized and all options exercised, this deal will be worth over $22B at current list prices, Ryanair stated, adding that it becomes the lead customer for this new aircraft, which for Ryanair will feature 197 seats and new CFM LEAP-1B engines.
09:33 EDTBARyanair places order for up to 200 Boeing 737 Max
Subscribe for More Information
07:15 EDTLLYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:01 EDTLLYIgnyta names Robert Wild as Chief Scientific Officer
Subscribe for More Information
06:47 EDTBARyanair to possibly place $10B Boeing order, Reuters says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use